Vir Biotechnology

State Street Corp increased its Vir Biotechnology stake by 10.4% in Q3, owning 5,625,533 shares worth $42,135,000. Other investors also adjusted positions, with institutional investors owning 65.32% of the stock. Vir Biotechnology's stock opened at $7.34 on Friday, with a 50-day moving average of $8.02 and a 200-day moving average of $8.55. The company reported a Q3 loss of $1.56 per share, missing estimates, and had revenue of $2.38 million, down 9.8% YoY. Analysts maintain a 'Moderate Buy' rating with an average target price of $36.40.

Y Intercept Hong Kong Ltd reduced its Vir Biotechnology shares by 78.4% in Q3, now holding 22,455 shares worth $168,000. Other investors adjusted their stakes, with Blue Trust Inc. increasing holdings by 143.5% and nVerses Capital LLC buying a new position valued at $56,000. Analysts predict Vir Biotechnology will post -3.36 earnings per share for the current fiscal year.

Vir Biotechnology's experimental treatment combination, tobevibart and elebsiran, for chronic hepatitis D, received FDA breakthrough therapy and EMA PRIME designations, based on Phase 2 SOLSTICE trial data showing effective viral suppression and liver damage normalization. The combo is well-tolerated and planned for Phase 3 ECLIPSE program.

Vir Biotechnology Inc. announced Marianne De Backer will present at the 43rd Annual J.P. Morgan Healthcare Conference on Jan 14, 4:30 p.m. PT. A live webcast will be available on Vir's website and archived for 30 days. Vir is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer.

Vir Biotechnology, a $1B immunology company, focuses on treating infectious diseases. It has a strong financial position, with more cash than debt and a current ratio of 8.94. Recent advancements in hepatitis treatments and strategic moves have attracted investor attention. The company's pipeline includes promising hepatitis programs and T-cell engagers, with potential peak annual revenues exceeding $10B. Despite financial losses and negative EPS estimates, Vir's strong balance sheet supports long-term growth initiatives.

Scientist and biotech stock trader focusing on trial results and FDA-regulated industries. Personal opinions on stocks, not investment advice. No current positions but may initiate a Long position in VIR within 72 hours. Written independently without compensation. Seeking Alpha's disclosure: Past performance not indicative of future results. No investment advice provided.

Vir Biotechnology's tobevibart and elebsiran received FDA Breakthrough Therapy and EMA Priority Medicines designations for chronic hepatitis delta, supported by Phase 2 SOLSTICE trial data. The Phase 3 ECLIPSE program will start in H1 2025.

Vir Biotechnology announced FDA Breakthrough Therapy and EMA PRIME designations for tobevibart and elebsiran in chronic hepatitis delta, supported by Phase 2 SOLSTICE trial data. The Phase 3 ECLIPSE program will start in H1 2025.